Epigenetics and type 1 diabetes: mechanisms and translational applications

Alberto Zullo; Linda Sommese; Gianfranco Nicoletti; Francesco Donatelli; Francesco P. Mancini; Claudio Napoli

doi:10.1016/j.trsl.2017.05.002

Epigenetics and type 1 diabetes: mechanisms and translational applications

Alberto Zullo, Linda Sommese, Gianfranco Nicoletti, Francesco Donatelli, Francesco P. Mancini, Claudio Napoli

IRCCS SDN

Research output: Contribution to journal › Review article › peer-review

Abstract

Type 1 diabetes (T1D) is an irreversible degenerative disease with severe complications such as heart disease, nephropathy, neuropathy, and retinopathy. Although exogenous insulin administration is a life-saving therapy, it does not cure the disease. This review addresses the epigenetic mechanisms responsible for the development of T1D and discusses epigenetic-based strategies for prevention and treatment of the disease. We describe novel epigenetic biomarkers for the identification of susceptible individuals and the establishment of innovative therapies with epidrugs and cell therapy to regenerate the lost β-cells. Despite the wealth of promising data regarding the potential benefits of epigenetic tools to reduce the burden of T1D, clinical trials are still very few, and this issue needs to be resolved in the near future.

Original language	English
Pages (from-to)	85-93
Number of pages	9
Journal	Translational Research
Volume	185
DOIs	https://doi.org/10.1016/j.trsl.2017.05.002
Publication status	Published - Jul 1 2017

ASJC Scopus subject areas

Public Health, Environmental and Occupational Health
Biochemistry, medical

Access to Document

10.1016/j.trsl.2017.05.002

Cite this

@article{d8f69b436468438cab852e5b460b5309,

title = "Epigenetics and type 1 diabetes: mechanisms and translational applications",

abstract = "Type 1 diabetes (T1D) is an irreversible degenerative disease with severe complications such as heart disease, nephropathy, neuropathy, and retinopathy. Although exogenous insulin administration is a life-saving therapy, it does not cure the disease. This review addresses the epigenetic mechanisms responsible for the development of T1D and discusses epigenetic-based strategies for prevention and treatment of the disease. We describe novel epigenetic biomarkers for the identification of susceptible individuals and the establishment of innovative therapies with epidrugs and cell therapy to regenerate the lost β-cells. Despite the wealth of promising data regarding the potential benefits of epigenetic tools to reduce the burden of T1D, clinical trials are still very few, and this issue needs to be resolved in the near future.",

author = "Alberto Zullo and Linda Sommese and Gianfranco Nicoletti and Francesco Donatelli and Mancini, {Francesco P.} and Claudio Napoli",

year = "2017",

month = jul,

day = "1",

doi = "10.1016/j.trsl.2017.05.002",

language = "English",

volume = "185",

pages = "85--93",

journal = "Translational Research",

issn = "1931-5244",

publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Epigenetics and type 1 diabetes

T2 - mechanisms and translational applications

AU - Zullo, Alberto

AU - Sommese, Linda

AU - Nicoletti, Gianfranco

AU - Donatelli, Francesco

AU - Mancini, Francesco P.

AU - Napoli, Claudio

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Type 1 diabetes (T1D) is an irreversible degenerative disease with severe complications such as heart disease, nephropathy, neuropathy, and retinopathy. Although exogenous insulin administration is a life-saving therapy, it does not cure the disease. This review addresses the epigenetic mechanisms responsible for the development of T1D and discusses epigenetic-based strategies for prevention and treatment of the disease. We describe novel epigenetic biomarkers for the identification of susceptible individuals and the establishment of innovative therapies with epidrugs and cell therapy to regenerate the lost β-cells. Despite the wealth of promising data regarding the potential benefits of epigenetic tools to reduce the burden of T1D, clinical trials are still very few, and this issue needs to be resolved in the near future.

AB - Type 1 diabetes (T1D) is an irreversible degenerative disease with severe complications such as heart disease, nephropathy, neuropathy, and retinopathy. Although exogenous insulin administration is a life-saving therapy, it does not cure the disease. This review addresses the epigenetic mechanisms responsible for the development of T1D and discusses epigenetic-based strategies for prevention and treatment of the disease. We describe novel epigenetic biomarkers for the identification of susceptible individuals and the establishment of innovative therapies with epidrugs and cell therapy to regenerate the lost β-cells. Despite the wealth of promising data regarding the potential benefits of epigenetic tools to reduce the burden of T1D, clinical trials are still very few, and this issue needs to be resolved in the near future.

UR - http://www.scopus.com/inward/record.url?scp=85020011263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020011263&partnerID=8YFLogxK

U2 - 10.1016/j.trsl.2017.05.002

DO - 10.1016/j.trsl.2017.05.002

M3 - Review article

C2 - 28552218

AN - SCOPUS:85020011263

SN - 1931-5244

VL - 185

SP - 85

EP - 93

JO - Translational Research

JF - Translational Research

ER -

Epigenetics and type 1 diabetes: mechanisms and translational applications

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this